Cantor Fitzgerald lowered the firm’s price target on Sanara MedTech to $44 from $49 and keeps an Overweight rating on the shares. Sanara’s core product, CellerateRX, is uniquely differentiated with an attractive margin profile n the $28B+ wound care market, and Cantor believes the company’s pipeline of products is under-appreciated, the analyst tells investors. The firm views the company’s shares as attractively valued relative to high-growth MedTech peers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMTI:
- Sanara MedTech’s Balancing Act: Navigating High Debt and Competitive Pressures in a Rising Rate Landscape
- SMTI Upcoming Earnings Report: What to Expect?
- Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates
- Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023
